Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01D VASODILATORS USED IN CARDIAC DISEASES
C01DX Other vasodilators used in cardiac diseases
C01DX22 Vericiguat
D11051 Vericiguat (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Vasodilators
Guanylate Cyclase (sGC) Stimulators
Vericiguat
D11051 Vericiguat (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D11051 Vericiguat (JAN/USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG03006 Guanylate cyclase activator
D11051 Vericiguat
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03183 UGT1A1 substrate
D11051 Vericiguat
DG03188 UGT1A9 substrate
D11051 Vericiguat
Target-based classification of drugs [BR:br08310]
Enzymes
Lyases (EC4)
Phosphorus-oxygen lyases
GUCY1A
D11051 Vericiguat (JAN/USAN/INN) <JP/US>
GUCY1B
D11051 Vericiguat (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11051
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11051
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11051
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11051
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11051